Multiple endocrine neoplasia syndrome type 1: clinical case

Multiple endocrine neoplasia syndrome type 1 (MEN 1, Wermer syndrome) is a group of heterogeneous inherited diseases, caused by hyperplasia or neoplastic transformation of several endocrine glands. MEN 1 syndrome is characterized by variable combinations of endocrine disorders. Cancer awareness in patient with diagnosed and genetically confirmed multiple endocrine neoplasia type 1 syndrome relatives plays an important role.
This case demonstrates a non-classical manifestation of the disease with neuroendocrine tumor of the pancreas, accompanied by hiperinsulinemic hypoglycemia, and the subsequent detection of primary hyperparathyroidism.

1. Brandi M.L., Pieterman C.R.C., English K.A., et al. Multiple endocrine neoplasia type 1 (MEN1). Lancet Diabetes Endocrinol. 2025; 13(8): 699–721.

2. Dedov E.I., Mel'nichenko G.A., Fadeev V.V. Endocrinology. Moscow: Litterra; 2024. 416. (in Russian)

3. Del Rivero J., Gangi A., Annes J.P., et al. American association of clinical endocrinology consensus statement on management of multiple endocrine neoplasia type 1. Endocr Pract. 2025; 31(4): 403–418.

4. English K. A., Pieterman C. R. C., Marini F., et al. Treatments for MEN1-associated endocrine tumours. Lancet Diabetes Endocrinol. 2025; 13(8): 685–698.

5. Manoharan J., Albers M. B., Rinke A., et al. Multiple endocrine neoplasia type 1: the current status of disease management. Dtsch Arztebl. Int. 2024; 121(16): 527–533.

6. Thakker R.V., Newey P.J., Walls G. V., et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012; 97(9): 2990–3011.

7. Singh G., Mulji N.J., Jialal I. Multiple endocrine neoplasia type 1. Treasure Island (FL) : StatPearls. Available at: https://www.ncbi.nlm.nih.gov/books/NBK536980/ (accessed: 20.12.2025).

8. Goudet P., Cadiot G., Barlier A., et al. French guidelines from the GTE, AFCE and ENDOCAN-RENATEN (Groupe d'etude des Tumeurs Endocrines/Association Francophone de Chirurgie Endocrinienne/Reseau national de prise en charge des tumeurs endocrines) for the screening, diagnosis and management of Multiple endocrine neoplasia type 1. Ann Endocrinol (Paris). 2024; 85(1): 2–19.

9. Cetani F., Dinoi E., Pierotti L., et al. Familial states of primary hyperparathyroidism. J Endocrinol Invest. 2024; 47(9): 2157–2176.

10. Eller-Vainicher C., Chiodini I., Battista C., et al. Sporadic and MEN1-related primary hyperparathyroidism: differences in clinical expression and severity. J Bone Miner Res. 2009; 24(8): 1404–1410.

11. Norton J.A., Krampitz G., Jensen R.T. Multiple endocrine neoplasia: genetics and clinical management. Surg Oncol Clin N Am. 2015; 24(4): 795–832.

12. Ito T., Igarashi H., Jensen R.T. Pancreatic neuroendocrine tumors: clinical features, diagnosis and medical treatment: advances. Best Pract Res Clin Gastroenterol. 2012; 26(6): 737–753.

13. De Leon D.D., Arnoux J.B., Banerjee I., et al. International guidelines for the diagnosis and management of hyperinsulinism. Horm Res Paediatr. 2024; 97(3): 279–329.

14. Clemente-Gutierrez U., Pieterman C.R.C., Lui M.S., et al. Beyond the three P's: adrenal involvement in MEN1. Endocr Relat Cancer. 2024; 31(2). doi: 10.1530/ERC-23-0162.

15. Hofland J., Falconi M., Christ E., et al. European Neuroendocrine Tumor Society 2023 guidance paper for functioning pancreatic neuroendocrine tumour syndromes. J Neuroendocrinol. 2023; 35(8). doi: 10.1111/jne.13318.